Study of inert cellulose powder effect on the nasal mucosa



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. To investigate the efficiency, safety of inert cellulose powder in allergic rhinitis, and influence
on mucous tunic of nasal cavity.
Materials and methods. Two groups of patients were examined in this research (30 healthy volunteers and
30 patients suffering from allergic rhinitis). The following factors of patients' life and health condition were
evaluated during the investigation: quality of life, the condition of mucous tunic, mucociliary clearance rate,
the ciliabeat frequency of ciliated cylindrical epithelium, the signs of inflammation in the smears of mucous
tunic before and after the treatment with Nazaval and Nazaval Plus.
The results. Nazaval and Nazaval Plus improved the quality of life index and reduced the inflammation signs
of mucous tunic of nasal cavity examined by rhinoscopy and endoscopy. No ciliotoxic effects of preparations
on mucous tunic were established.
Conclusion. The inert cellulose powder is a highly effective and safe product for the treatment of allergic
rhinitis.

About the authors

I B Angotoeva

Email: Angotoeva@mail.ru

E V Sukhovetchenko

I B Angotoeva

Russian Medical Academy of Postgraduate Education

Russian Medical Academy of Postgraduate Education

E V Suhovetchenko

Russian Medical Academy of Postgraduate Education

Russian Medical Academy of Postgraduate Education

References

  1. Sibbald В., Rink E. Epidemiology of seasonal and perennial rhinitis: clinical presentation and medical history. Thorax. 1991, v. 46, p. 895-901.
  2. Katelaris C.H., Lee B W., Potter P. С., Maspero J.F., Cingi C., Lopatin A. et al. Prevalence and diversity of allergic rhinitis in regions ofthe world beyond Europe and North America. Clin. Exp. Allergy. 2011 (в печати).
  3. Лопатин А.С. Ринит. М., «Литтерра». 2010.
  4. ARIA. Allergic rhinitis and its impact on asthma. WHO initiative, 2001.
  5. Гущин И.С. Аллергическое воспаление и его фармакологический контроль. М., «Фармарус Принт». 1998, 252 с.
  6. Ciprandi G., Cirillo I., Vizzaccaro A., Tosca M.A. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study Clin. Exp. Allergy. 2004, v. 34, p. 958-964.
  7. Ciprandi G., Cirillo I., Vizzaccaro A., Civardi E. et al. Dezloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennialallergic rhinitis: A pilot study. International Immunopharmacology 2005, v. 5, p. 1800-1808.
  8. Mahmound F., Arifhodzic N., Haines D., Novotney L. Levocetirizine modulates lymphocyte activation in patients with allergic rhinitis. J. Pharmacol. Sci. 2008, v. 108, p. 149-156.
  9. Day J.H., Briscoe M.R., Rafeiro E., Ratz J.D. Comparative clinical efficacy, onset and duration of action levocetirizine and dezloratadine for symptoms of seasonal allergic rhinitis in subject evaluated in the Environmental Exposure Unit (EEU). Int. J. Clin. Pract. 2004, v. 58, 2, p. 109-118.
  10. Jorissen M., Bertrand B., Stiels B., Vandenbulcke K. Levocetirizine as treatment for symptoms of seasonal allergic rhinitis. B-ENT 2006, v. 2, p. 55-62.
  11. Canonica G.W., Fumagalli F., Guerra L., Baiardini I. et al. Levocetirizine in persistent allergic rhinitis: continuos or on-demand use? A pilot study. Current medical research and opinion. 2008, v. 24, 10, p. 2829-2839.
  12. Lombardo G., Quattrocchi P., Lombardo G.R., Galati P. et al. Concomitant levocetirizine and montelukast in the treatment of seasonal allergic rhinitis: influence on clinical symptoms. J. Allergy Clin. Immunol. 2006, v. 16, p. 63-68.
  13. Patel P., Patel D. Efficacy comparison of levocetirizine vs montelucast in ragweed sensitized patients. Ann. Allergy Asthma Immunol. 2008, v. 101, p. 287-294

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright © Pharmarus Print Media, 1970



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies